PT1124546E - Um metodo para prevenir reduzir e tratar a cistite usando acido hialuronico - Google Patents

Um metodo para prevenir reduzir e tratar a cistite usando acido hialuronico

Info

Publication number
PT1124546E
PT1124546E PT99952186T PT99952186T PT1124546E PT 1124546 E PT1124546 E PT 1124546E PT 99952186 T PT99952186 T PT 99952186T PT 99952186 T PT99952186 T PT 99952186T PT 1124546 E PT1124546 E PT 1124546E
Authority
PT
Portugal
Prior art keywords
hyaluronic acid
preventing
reducing
treating cystitis
preventing reducing
Prior art date
Application number
PT99952186T
Other languages
English (en)
Inventor
Peter J Pommerville
Original Assignee
Bioniche Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioniche Life Sciences Inc filed Critical Bioniche Life Sciences Inc
Publication of PT1124546E publication Critical patent/PT1124546E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT99952186T 1998-10-22 1999-10-22 Um metodo para prevenir reduzir e tratar a cistite usando acido hialuronico PT1124546E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10518498P 1998-10-22 1998-10-22

Publications (1)

Publication Number Publication Date
PT1124546E true PT1124546E (pt) 2004-08-31

Family

ID=22304511

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99952186T PT1124546E (pt) 1998-10-22 1999-10-22 Um metodo para prevenir reduzir e tratar a cistite usando acido hialuronico

Country Status (12)

Country Link
US (2) US6667296B1 (pt)
EP (1) EP1124546B1 (pt)
JP (1) JP4685242B2 (pt)
AT (1) ATE264674T1 (pt)
AU (1) AU761158B2 (pt)
CA (1) CA2347110C (pt)
DE (1) DE69916643T2 (pt)
DK (1) DK1124546T3 (pt)
ES (1) ES2219070T3 (pt)
NZ (1) NZ511068A (pt)
PT (1) PT1124546E (pt)
WO (1) WO2000024387A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9906619D0 (en) 1999-03-23 1999-05-19 Zeneca Resins Bv Compositions
WO2005058235A2 (en) * 2003-12-10 2005-06-30 Keryx Biopharmaceuticals, Inc. Methods using sulodexide for the treatment of bladder disease
JP2007233949A (ja) * 2006-03-03 2007-09-13 Kyoto Univ 排尿管理システム
ITMI20061030A1 (it) 2006-05-26 2007-11-27 Altergon Sa Nuova composizione comprendente glicosamminoglicani a viscosita' controllata e uso di tale composizione nella terapuia della cistite cronica
DE102006060953A1 (de) 2006-12-12 2008-08-07 Farco-Pharma Gmbh Pharmazeutische Zubereitung für die Behandlung entzündlicher Erkrankungen des Urogenitaltraktes
HUP0900717A3 (en) * 2009-11-18 2012-02-28 Richter Gedeon Nyrt Pharmaceutical composition for urological use containing zinc hyaluronate
EP3960215B1 (en) 2009-12-15 2024-10-16 Incept, LLC Implants and biodegradable fiducial markers
RU2557949C1 (ru) * 2014-08-14 2015-07-27 Общество с ограниченной ответственностью "КОЛЕТЕКС" Способ лечения лучевого и интерстициального цистита
US20180055822A1 (en) * 2015-03-13 2018-03-01 Repoceuticals Aps Melatonin for Preventing and Treating Radiation Cystitis
RU2676431C1 (ru) * 2018-02-26 2018-12-28 Федеральное государственное бюджетное учреждение "Российский научный центр радиологии и хирургических технологий имени академика А.М. Гранова" Министерства здравоохранения Российской Федерации (ФГБУ "РНЦРХТ им. ак. А.М. Гранова" Минздрава России) Способ моделирования лучевого цистита
CA3102284A1 (en) * 2018-06-03 2019-12-12 Glycomira Therapeutics, Inc. Methods for preventing a serious health consequence and/or tissue damage after exposure to ionizing radiation and/or chemotherapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880108A (en) 1995-02-14 1999-03-09 Bioniche, Inc. Method for treating the internal urinary bladder and associated structures using hyaluronic acid
IN181358B (pt) * 1995-02-14 1998-05-30 Bioniche Inc
CA2154103C (en) 1995-07-18 1998-02-24 Samuel Simon Asculai Treatment of mucous membrane disease, trauma or condition and for the relief of pain
CA2247389C (en) 1996-12-27 2009-11-24 Seikagaku Corporation Agent for treatment of bladder troubles

Also Published As

Publication number Publication date
NZ511068A (en) 2003-10-31
ES2219070T3 (es) 2004-11-16
WO2000024387A3 (en) 2000-08-03
EP1124546B1 (en) 2004-04-21
DK1124546T3 (da) 2004-08-09
DE69916643D1 (de) 2004-05-27
DE69916643T2 (de) 2005-04-28
AU6455899A (en) 2000-05-15
ATE264674T1 (de) 2004-05-15
JP2002528410A (ja) 2002-09-03
AU761158B2 (en) 2003-05-29
CA2347110A1 (en) 2000-05-04
JP4685242B2 (ja) 2011-05-18
EP1124546A2 (en) 2001-08-22
US6667296B1 (en) 2003-12-23
WO2000024387A2 (en) 2000-05-04
US20040152662A1 (en) 2004-08-05
CA2347110C (en) 2008-08-26

Similar Documents

Publication Publication Date Title
LTIP1669A (en) Cetirizine-containing antialergic solution for opthalmic or nasal use
PT1124546E (pt) Um metodo para prevenir reduzir e tratar a cistite usando acido hialuronico
DE60023138D1 (de) Verwendung eines biologisch abbaubaren Polymers
ATE288270T1 (de) Mikroverkapselte 1,2-benzazole
PT1073470E (pt) Composicoes farmaceuticas contendo compostos com actividade capaz de melhorar a absorcao de ingredientes activos
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
BR0112361A (pt) Métodos para tratamento de condições oculares mediadas por inflamação
CA2390295A1 (en) A method for chemoprevention of prostate cancer
WO2002076499A3 (en) Combination treatment of pancreatic cancer
AU3475097A (en) Substituted cyclopentane compounds useful as neuraminidase inhibitors
BR9811099A (pt) Inibidores de urocinase
BR0009063A (pt) Composições de resina de epóxido estáveis aarmazenamento
NO953995D0 (no) Ionenolymere som anthelmintica i dyr
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
BR9707247A (pt) Diidrobenzofurano e compostos relacionados úteis como agentes antiinflamatórios
EE04660B1 (et) Ravim artriitiliste haiguste raviks
DK1269860T3 (da) Farmaceutisk præparat
DE69519385D1 (de) Chinazolinon-arzneimittel sowie deren verwendung
ATE217800T1 (de) Bioabbaubare, injizierbare oligomer-polymer- zusammensetzung
UY25338A1 (es) Método para tratar copd
ATE425731T1 (de) Pharmazeutische zusammensetzungen eines nichtmagensaftresistenten protonenpumpen-hemmers mit einer carbonat- und bicarbonatsalzkombination
EP0974358A3 (en) Orally-administrable therapeutic and/or prophylactic agent for HTLV-1-related diseases
WO2000047197A3 (en) Alkylating agents for treatment of cellular proliferation
AU4937499A (en) Use of succinic acid or salts thereof and method of treating insulin resistance
TR200101346T2 (tr) Rilüzol ve alfa-tokoferol bileşimi